Renaissance Technologies LLC Decreases Stock Position in Sotera Health Company $SHC

Renaissance Technologies LLC lessened its stake in shares of Sotera Health Company (NASDAQ:SHC) by 52.4% in the 1st quarter, Holdings Channel reports. The firm owned 203,078 shares of the company’s stock after selling 223,700 shares during the period. Renaissance Technologies LLC’s holdings in Sotera Health were worth $2,912,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. IFP Advisors Inc lifted its position in shares of Sotera Health by 1,105.6% in the fourth quarter. IFP Advisors Inc now owns 1,495 shares of the company’s stock worth $26,000 after buying an additional 1,371 shares in the last quarter. Rothschild Investment LLC purchased a new position in Sotera Health during the 4th quarter valued at approximately $27,000. Root Financial Partners LLC grew its holdings in Sotera Health by 217.5% during the 1st quarter. Root Financial Partners LLC now owns 2,124 shares of the company’s stock valued at $30,000 after buying an additional 1,455 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Sotera Health by 831.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock worth $37,000 after acquiring an additional 2,935 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Sotera Health in the 4th quarter worth approximately $40,000. 91.03% of the stock is owned by institutional investors.

Sotera Health News Roundup

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Wall Street Analysts Forecast Growth

SHC has been the subject of a number of research reports. Weiss Ratings upgraded Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 9th. UBS Group set a $19.00 price target on shares of Sotera Health in a research report on Wednesday, June 24th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of Sotera Health in a research note on Friday. Wall Street Zen lowered shares of Sotera Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.50.

Sotera Health Price Performance

NASDAQ:SHC opened at $18.86 on Friday. The firm has a market capitalization of $5.38 billion, a price-to-earnings ratio of 33.09 and a beta of 1.77. Sotera Health Company has a 1 year low of $12.94 and a 1 year high of $19.85. The business has a 50 day simple moving average of $17.13 and a 200-day simple moving average of $16.33. The company has a debt-to-equity ratio of 3.19, a current ratio of 2.80 and a quick ratio of 2.54.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Thursday, August 6th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The firm had revenue of $321.38 million during the quarter, compared to analysts’ expectations of $309.70 million. During the same quarter in the previous year, the business earned $0.20 EPS. The company’s quarterly revenue was up 9.2% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Equities analysts forecast that Sotera Health Company will post 0.87 EPS for the current year.

Insider Buying and Selling

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of Sotera Health stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total transaction of $193,194,516.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 15.36% of the stock is owned by insiders.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.